News

The U.S. Senate has joined the House of Representatives in approving The National Plan to End Parkinson’s Act, the first piece of federal legislation dedicated to ending Parkinson’s disease. Celebrated by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), the bill now will be sent to…

Physical exercise may reduce the risk of developing Parkinson’s disease, as well as effectively control patients’ symptoms, according to a review analysis by researchers in Europe. Moreover, some studies suggest that exercise might be a potential disease-modifying treatment, working to slow disease progression and stabilizing, or even reducing, the…

In a first-of-its-kind development, a team of scientists created a lab model of the blood-brain barrier (BBB) surrounding the brain. The new model represents “a game-changing technology with broad implications for neuroscience, drug discovery, and personalized medicine,” Ziyuan Guo, PhD, assistant professor at the University of Cincinnati department of pediatrics…

The European Inventor Award 2024 has named as finalists a French husband-and-wife team of scientists who developed a dosing pump that allows for direct delivery of dopamine to the brain in people with Parkinson’s disease. The use of dopamine is expected to help reduce symptoms and so-called off…

A diagnostic panel of four biomarkers that combines the blood levels of a molecule called N-acetylputrescine (NAP) with three clinical features often present in Parkinson’s disease — loss of smell, depression, and acting out dreams — may help identify the disease at its earlier stages, a study found. The…

Serina Therapeutics has partnered with Enable Injections to advance SER-252 (POZ-apomorphine), Serina’s lead treatment candidate for advanced Parkinson’s disease, in combination with the enFuse wearable delivery system. EnFuse is designed to allow patients to self-administer SER-252 subcutaneously (under the skin) in a faster, simpler, and more…

An oral spray was safe and efficient at delivering apomorphine to people with Parkinson’s disease, a study found. A subcutaneous injection formulation of apomorphine, sold as Apokyn, is approved in the U.S. to treat off episodes — periods in which symptoms return between doses of levodopa treatment — in…

A region in the alpha-synuclein protein has been identified as a possible target for inhibiting the conversion of oligomers — early aggregates, or clumps, of the protein — into toxic fibrils, a hallmark of Parkinson’s disease, according to a recent study. Mutations in this region are also associated with…

An adult with early-onset Parkinson’s disease, who is nearing age 50, will compete on the world stage this summer as a mixed-doubles rower at the Paralympic Games in Paris. Todd Vogt of Portland, Oregon, who was diagnosed in 2018 with early-onset Parkinson’s at age 43, will represent…

Aspen Neuroscience has been awarded an $8 million grant to advance the clinical development of ANPD001, its investigational stem cell therapy that’s designed to replace dopamine-producing nerve cells lost in Parkinson’s disease. The grant, funded by the California Institute for Regenerative Medicine (CIRM), will support the ongoing Phase…